Custom Search

Sunday, August 15, 2010

ANDA CHECKLIST FOR CTD or eCTD FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING.

ANDA CHECKLIST FOR CTD or eCTD FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING.

Here are the details of an ANDA , what are the necessary documentation's; requirements which are needed to be fulfilled in an ANDA.

ANDA #:
FIRM NAME:
PIV:

ELECTRONIC OR PAPER SUBMISSION:
RELATED APPLICATION(S):

First Generic Product Received?


DRUG NAME:


DOSAGE FORM:
Bio Assignments: BPH ? BCE ? BST ? BDI ? Micro Review ?

Random Queue:
Chem Team Leader: PM: Labeling Reviewer:
Comments:
On Cards:
Therapeutic Code:

Archival copy:
Sections
Review copy:
E-Media Disposition:
Not applicable to electronic sections
PART 3 Combination Product Category

(Must be completed for ALL Original Applications) Refer to the Part 3 Combination Algorithm

====================================================================================================
1.1 1.1.2 Signed and Completed Application Form (356h) (original signature)
(Check Rx/OTC Status)
1.2 Cover Letter
1.2.1 Form FDA 3674 (PDF)

 Contents (paper submission only)
1.3.2 Field Copy Certification (original signature)
(N/A for E-Submissions)
1.3.3 Debarment Certification-GDEA (Generic Drug Enforcement Act)/Other:
1. Debarment Certification (original signature)
2. List of Convictions statement (original signature)
1.3.4 Financial Certifications
Bioavailability/Bioequivalence Financial Certification (Form FDA 3454)
Disclosure Statement (Form FDA 3455, submit copy to Regulatory Branch Chief)
1.3.5
1.3.5.1 Patent Information
Patents listed for the RLD in the Electronic Orange Book Approved Drug Products with
Therapeutic Equivalence Evaluations
1.3.5.2 Patent Certification
1. Patent number(s)
2. Paragraph: (Check all certifications that apply)
MOU PI PII PIII
PIV (Statement of Notification)
3. Expiration of Patent(s):
a. Pediatric exclusivity submitted?
b. Expiration of Pediatric Exclusivity?
4. Exclusivity Statement:
1.4.1 References
Letters of Authorization
1. DMF letters of authorization
a. Type II DMF authorization letter(s) or synthesis for Active Pharmaceutical
Ingredient
b. Type III DMF authorization letter(s) for container closure
2. US Agent Letter of Authorization (U.S. Agent [if needed, countersignature on
356h])
1.12.11 Basis for Submission
NDA# :
Ref Listed Drug:
Firm:
ANDA suitability petition required?
If Yes, then is change subject to PREA (change in dosage form, route or active ingredient) see section 1.9.1
1.12.12 Comparison between Generic Drug and RLD-505(j)(2)(A)
1. Conditions of use
2. Active ingredients
3. Inactive ingredients
4. Route of administration
5. Dosage Form
6. Strength
1.12.14 Environmental Impact Analysis Statement
1.12.15 Request for Waiver Request for Waiver of In-Vivo BA/BE Study(ies):
1.14.1 Draft Labeling (Mult Copies N/A for E-Submissions)
1.14.1.1 4 copies of draft (each strength and container)
1.14.1.2 1 side by side labeling comparison of containers and carton with all differences
annotated and explained
1.14.1.3
1 package insert (content of labeling) submitted electronically
***Was a proprietary name request submitted?
(If yes, send email to Labeling Reviewer indicating such)
1.14.3 Listed Drug Labeling
1.14.3.1
1 side by side labeling (package and patient insert) comparison with all differences
annotated and explained
1.14.3.3
1 RLD label and 1 RLD container label
MODULE 2
2.3 Quality Overall Summary (QOS)
E-Submission: PDF
Word Processed e.g., MS Word
A model Quality Overall Summary for an immediate release tablet and an extended release capsule can be found on the OGD webpage http://www.fda.gov/cder/ogd/
Question based Review (QbR)
2.3.S Drug Substance (Active Pharmaceutical Ingredient)
2.3.S.1 General Information
2.3.S.2 Manufacture
2.3.S.3 Characterization
2.3.S.4 Control of Drug Substance
2.3.S.5 Reference Standards or Materials
2.3.S.6 Container Closure System
2.3.S.7 Stability
2.3.P Drug Product
2.3.P.1 Description and Composition of the Drug Product
2.3.P.2 Pharmaceutical Development
2.3.P.2.1 Components of the Drug Product
2.3.P.2.1.1 Drug Substance
2.3.P.2.1.2 Excipients
2.3.P.2.2 Drug Product
2.3.P.2.3 Manufacturing Process Development
2.3.P.2.4 Container Closure System
2.3.P.3 Manufacture
2.3.P.4 Control of Excipients
2.3.P.5 Control of Drug Product
2.3.P.6 Reference Standards or Materials
2.3.P.7 Container Closure System
2.3.P.8 Stability
2.7 Clinical Summary (Bioequivalence)
Model Bioequivalence Data Summary Tables
E-Submission: PDF
Word Processed e.g., MS Word
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.1.1 Background and Overview
Table 1. Submission Summary
Table 4. Bioanalytical Method Validation
Table 6. Formulation Data
2.7.1.2 Summary of Results of Individual Studies
Table 5. Summary of In Vitro Dissolution
2.7.1.3 Comparison and Analyses of Results Across Studies
Table 2. Summary of Bioavailability (BA) Studies
Table 3. Statistical Summary of the Comparative BA Data
2.7.1.4 Appendix
2.7.4.1.3 Demographic and Other Characteristics of Study Population
Table 7. Demographic Profile of Subjects Completing the Bioequivalence Study
2.7.4.2.1.1 Common Adverse Events
Table 8. Incidence of Adverse Events in Individual Studies
MODULE 3
3.2.S DRUG SUBSTANCE ACCEPTABLE
3.2.S.1 General Information
3.2.S.1.1 Nomenclature
3.2.S.1.2 Structure
3.2.S.1.3 General Properties
3.2.S.2 Manufacturer
3.2.S.2.1 Manufacturer(s) (This section includes contract manufacturers and testing labs)
Drug Substance (Active Pharmaceutical Ingredient)
1. Name and Full Address(es)of the Facility(ies)
2. Function or Responsibility
3. Type II DMF number for API
4. CFN or FEI numbers
3.2.S.3 Characterization
3.2.S.4 Control of Drug Substance (Active Pharmaceutical Ingredient)
3.2.S.4.1 Specification
Testing specifications and data from drug substance manufacturer(s)
3.2.S.4.2 Analytical Procedures
3.2.S.4.3 Validation of Analytical Procedures
1. Spectra and chromatograms for reference standards and test samples
2. Samples-Statement of Availability and Identification of:
a. Drug Substance
b. Same lot number(s)
3.2.S.4.4 Batch Analysis
1. COA(s) specifications and test results from drug substance mfgr(s)
2. Applicant certificate of analysis
3.2.S.4.5 Justification of Specification
3.2.S.5 Reference Standards or Materials
3.2.S.6 Container Closure Systems
3.2.S.7 Stability
3.2.P DRUG PRODUCT ACCEPTABLE
3.2.P.1 Description and Composition of the Drug Product
1. Unit composition
2. Inactive ingredients and amounts are appropriate per IIG
3.2.P.2 Pharmaceutical Development
Pharmaceutical Development Report
3.2.P.3 Manufacture
3.2.P.3.1 Manufacture(s) (Finished Dosage Manufacturer and Outside Contract Testing Laboratories)
1. Name and Full Address(es)of the Facility(ies)
2. CGMP Certification:
3. Function or Responsibility
4. CFN or FEI numbers
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
1. Description of the Manufacturing Process
2. Master Production Batch Record(s) for largest intended production runs
(no more than 10x pilot batch) with equipment specified
3. If sterile product: Aseptic fill / Terminal sterilization
4. Reprocessing Statement
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
1. Microbiological sterilization validation
2. Filter validation (if aseptic fill)
3.2.P.4 Controls of Excipients (Inactive Ingredients)
Source of inactive ingredients identified
3.2.P.4.1 Specifications
1. Testing specifications (including identification and characterization)
2. Suppliers' COA (specifications and test results)
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
Applicant COA
3.2.P DRUG PRODUCT
3.2.P.5 Controls of Drug Product
3.2.P.5.1 Specification(s)
3.2.P.5.2 Analytical Procedures
3.2.P.5.3 Validation of Analytical Procedures
Samples - Statement of Availability and Identification of:
1. Finished Dosage Form
2. Same lot numbers
3.2.P.5.4 Batch Analysis
Certificate of Analysis for Finished Dosage Form
3.2.P.5.5 Characterization of Impurities
3.2.P.5.6 Justification of Specifications
3.2.P.7 Container Closure System
1. Summary of Container/Closure System (if new resin, provide data)
2. Components Specification and Test Data
3. Packaging Configuration and Sizes
4. Container/Closure Testing
5. Source of supply and suppliers address
3.2.P.8
3.2.P.8.1 Stability (Finished Dosage Form)
1. Stability Protocol submitted
2. Expiration Dating Period
3.2.P.8.2 Post-approval Stability and Conclusion
Post Approval Stability Protocol and Commitments
3.2.P.8.3 Stability Data
1. 3 month accelerated stability data
2. Batch numbers on stability records the same as the test batch

3.2.R Regional Information
3.2.R (Drug Substance)
3.2.R.1.S Executed Batch Records for drug substance (if available)
3.2.R.2.S Comparability Protocols
3.2.R.3.S Methods Validation Package
Methods Validation Package (3 copies) (Mult Copies N/A for E-Submissions)
(Required for Non-USP drugs)
3.2.R (Drug Product)
3.2.R.1.P.1
Executed Batch Records
Copy of Executed Batch Record with Equipment Specified, including Packaging Records
(Packaging and Labeling Procedures)
Batch Reconciliation and Label Reconciliation
Theoretical Yield
Actual Yield
Packaged Yield
3.2.R.1.P.2 Information on Components
3.2.R.2.P Comparability Protocols
3.2.R.3.P Methods Validation Package
Methods Validation Package (3 copies) (Mult Copies N/A for E-Submissions)
(Required for Non-USP drugs)
MODULE 5
CLINICAL STUDY REPORTS ACCEPTABLE
5.2 Tabular Listing of Clinical Studies
5.3.1 (complete study data)
Bioavailability/Bioequivalence
1. Formulation data same?
a. Comparison of all Strengths (check proportionality of multiple strengths)
b. Parenterals, Ophthalmics, Otics and Topicals
per 21 CFR 314.94 (a)(9)(iii)-(v)
2. Lot Numbers of Products used in BE Study(ies):
3. Study Type: (Continue with the appropriate study type box below)
5.3.1.2 Comparative BA/BE Study Reports
1. Study(ies) meets BE criteria (90% CI of 80-125, C max, AUC)
2. Summary Bioequivalence tables:
Table 10. Study Information
Table 12. Dropout Information
Table 13. Protocol Deviations
5.3.1.3 In Vitro-In-Vivo Correlation Study Reports
1. Summary Bioequivalence tables:
Table 11. Product Information
Table 16. Composition of Meal Used in Fed Bioequivalence Study
5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies
1. Summary Bioequivalence table:
Table 9. Reanalysis of Study Samples
Table 14. Summary of Standard Curve and QC Data for Bioequivalence Sample
Analyses
Table 15. SOPs Dealing with Bioanalytical Repeats of Study Samples
5.3.7 Case Report Forms and Individual Patient Listing
5.4 Literature References
Possible Study Types:
Study Type
IN-VIVO BE STUDY(IES) with PK ENDPOINTS (i.e., fasting/fed/sprinkle)
1. Study(ies) meets BE criteria (90% CI of 80-125, C max, AUC)
2. EDR Email: Data Files Submitted: YES SENT TO EDR
3. In-Vitro Dissolution:
Study Type
IN-VIVO BE STUDY with CLINICAL ENDPOINTS
1. Properly defined BE endpoints (eval. by Clinical Team)
2. Summary results meet BE criteria: 90% CI of the proportional difference in success rate between test and
reference must be within (-0.20, +0.20) for a binary/dichotomous endpoint. For a continuous endpoint, the
test/reference ratio of the mean result must be within (0.80, 1.25).
3. Summary results indicate superiority of active treatments (test & reference) over vehicle/placebo
(p<0.05) (eval. by Clinical Team)
4. EDR Email: Data Files Submitted
Study Type
IN-VITRO BE STUDY(IES) (i.e., in vitro binding assays)
1. Study(ies) meets BE criteria (90% CI of 80-125)
2. EDR Email: Data Files Submitted:
3. In-Vitro Dissolution:
Study Type
NASALLY ADMINISTERED DRUG PRODUCTS
1. Solutions (Q1/Q2 sameness):
a. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern,
Plume Geometry, Priming & Repriming)
2. Suspensions (Q1/Q2 sameness):
a. In-Vivo PK Study
1. Study(ies) meets BE Criteria (90% CI of 80-125, C max, AUC)
2. EDR Email: Data Files Submitted
b. In-Vivo BE Study with Clinical End Points
1. Properly defined BE endpoints (eval. by Clinical Team)
2. Summary results meet BE criteria (90% CI within +/- 20% of 80-125)
3. Summary results indicate superiority of active treatments (test & reference) over
vehicle/placebo (p<0.05) (eval. by Clinical Team)
4. EDR Email: Data Files Submitted
c. In-Vitro Studies (Dose/Spray Content Uniformity, Droplet/Drug Particle Size Distrib., Spray Pattern,
Plume Geometry, Priming & Repriming)
Study Type
IN-VIVO BE STUDY(IES) with PD ENDPOINTS (e.g., topical corticosteroid vasoconstrictor
studies)
1. Pilot Study (determination of ED50)
2. Pivotal Study (study meets BE criteria 90%CI of 80-125)
Study Type
TRANSDERMAL DELIVERY SYSTEMS
1. In-Vivo PK Study
1. Study(ies) meet BE Criteria (90% CI of 80-125, C max, AUC)
2. In-Vitro Dissolution
3. EDR Email: Data Files Submitted
2. Adhesion Study 3. Skin Irritation/Sensitization Study

US FDA updates its documentation's requirements , so you should take and checkelist for eCTD , CTD from US FDA'S website.
=======================================================================
What is What is 510(k) Clearances ?
What is 510(k) Clearances, Premarket Notification for medical devices - PMN or 510(k)


Antibiotic Definition and classification


Antibiotic resitance and Drug resistance mechanism

Antioxidants food suppliments

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D


What is an antibody? what is monoclonal and polyclonal antibodies?


Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

http://whoguideline.blogspot.com/2010/04/terminalogy-and-their-explanations.html

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

http://whoguideline.blogspot.com/2010/02/pharmaceutical-aseptic-manufacturing.html

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing


Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Cleen Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detaied information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs

BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS

Electronic record in pharmaceutical manufacturing industry


Standard Operating Procedure ,(SOP)
Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates

Here is an interesting article on world wide pharmaceutical industry
Article on Pharmaceutical Industry pharmaceutical industry

Here are some interesting articles on Quality assurance systems for pharmaceutical company

1.Quality assurance in pharma industry

2.Quality by designe concept for pharmaceutical industry

3.Quality by designe concept in pharmaceutical industryan explanation

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org